INTS - Intensity Therapeutics, Inc. Common stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
0.29 -0.02 (-5.83%)	---	0.0 (0.0%)	-0.01 (-2.25%)	-0.01 (-3.1%)	-0.01 (-2.64%)	0.0 (-1.3%)	0.0 (-1.3%)

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.13
Diluted EPS:: -0.13
Basic P/E:: -2.1008
Diluted P/E:: -2.1008
RSI(14) 1m:: 50.37
VWAP:: 0.27
RVol:

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	0.27 -0.01 (-2.15%)	Oct 15 19:32
1m	Price decrease 1m	0.28 -0.0 (-1.36%)	Oct 15 19:01
1m	Price decrease 1m	0.28 -0.0 (-1.61%)	Oct 15 18:55
1m	Price increase 1m	0.28 +0.01 (+2.94%)	Oct 15 17:27
1m	Price decrease 1m	0.27 -0.0 (-1.21%)	Oct 15 17:25